+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-vascular Endothelial Growth Factor Therapeutics Market by Product Type, Therapeutic Area, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Anti-vascular Endothelial Growth Factor Therapeutics Market by Product Type, Therapeutic Area, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Anti-vascular Endothelial Growth Factor Therapeutics Market by Product Type, Therapeutic Area, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5716142
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Anti-vascular Endothelial Growth Factor (VEGF) Therapeutics Market is experiencing robust growth, expanding from USD 9.01 billion in 2024 to USD 9.87 billion in 2025, with projections indicating a continued rise to USD 15.39 billion by 2030 at a CAGR of 9.33%. This market evolution is driven by the transformative impact of anti-VEGF treatments in managing retinal vascular diseases, reflecting a new era of therapeutic innovation and patient care improvement.

Setting the Stage for a New Era in Anti-VEGF Therapeutics

Anti-VEGF therapies have revolutionized the treatment landscape for retinal diseases by significantly reducing the occurrence of vision loss. This report details the diverse therapeutic options available, emerging clinical evidence, and changing patient needs impacting the market. It explores critical trends and strategic imperatives that are redrawing the boundaries of the anti-VEGF field.

Evolving Dynamics Reshaping the Anti-VEGF Landscape

Significant innovations in the anti-VEGF sector include sustained-release formulations and advancements in gene therapy vectors, which promise long-term benefits from fewer doses. The integration of digital health platforms for remote retinal health monitoring has further personalized treatment regimens. Meanwhile, the emergence of biosimilars is creating competitive pricing pressures, prompting companies to optimize lifecycle management strategies. These advancements highlight the necessity for agility and evidence-based decision-making to maintain a competitive advantage in the industry.

Navigating the Ripple Effects of US Tariffs on Supply Chains

The introduction of tariffs on biologic materials has escalated production costs and ushered in supply chain realignments for manufacturers. Companies are now reconsidering supplier contracts and exploring domestic manufacturing options to mitigate tariff-induced cost pressures. This strategic refocusing helps maintain competitive pricing while safeguarding patient access and supply reliability through innovative procurement practices.

Diving Deep into Market Segmentation Nuances

The market segmentation across product types, therapeutic areas, and administration modalities reveals key drivers of adoption and growth. Key therapeutic products include aflibercept, bevacizumab, brolucizumab, and ranibizumab, each with unique molecular configurations and dosing regimens. Market use cases span age-related macular degeneration, diabetic macular edema, and other retinal conditions, influencing prescribing behavior. Distribution channels play a critical role, shaping access and reimbursement dynamics, while end users ranging from hospitals to specialty clinics form the backbone of the market.

Uncovering Regional Variations that Drive Growth

Regional dynamics exhibit significant disparities in market maturity and growth prospects. While the Americas lead with established clinical trials and reimbursement frameworks, Europe, the Middle East & Africa show varied market conditions driven by regulatory and pricing strategies. In the Asia-Pacific, burgeoning patient populations and advancing healthcare policies drive sectoral expansion. Understanding these regional disparities enables tailored market entry strategies and resource allocation to capitalize on growth opportunities.

Strategies and Innovations from Leading Therapeutic Developers

Key players in the anti-VEGF market are spearheading innovations with next-generation formulations and strategic alliances. Companies like Regeneron, Genentech, and Novartis are enhancing therapy effectiveness through new delivery systems and long-term safety studies. Emerging contenders are exploring biosimilar and biobetter candidates, often via collaborations and licensing arrangements. Such strategic maneuvers underscore the industry's commitment to innovation and operational excellence.

Strategic Actions to Stay Ahead in a Competitive Arena

Decision-makers are encouraged to align R&D efforts with unmet clinical needs, adopt personalized medicine approaches, and bolster supply chain resilience. Real-time monitoring tools and outcome-based contracting with payors can improve therapy adherence and justify premium pricing. These strategic actions are crucial for addressing policy changes and maintaining leadership in a dynamic market.

Comprehensive Approach to Data Collection and Analysis

This report integrates insights from primary and secondary research methodologies to offer an encompassing view of the anti-VEGF market. In-depth interviews with industry experts and quantitative modeling validate observed trends and sector performance across diverse segments. This comprehensive data synthesis provides strategic insights essential for risk mitigation and opportunity identification.

Synthesizing Insights to Inform Strategic Decisions

The fusion of clinical innovation, policy shifts, and market dynamics will continue shaping the anti-VEGF sector's future. Firms that integrate segmentation drivers and regional nuances can achieve targetted market entry and resource deployment. Collaborative ventures among stakeholders will unlock value, facilitating growth and market leadership.

Market Segmentation & Coverage

  • Product Type:
    • Aflibercept
    • Bevacizumab
    • Brolucizumab
    • Ranibizumab
  • Therapeutic Area:
    • Age Related Macular Degeneration
    • Diabetic Macular Edema
    • Myopic Choroidal Neovascularization
    • Retinal Vein Occlusion
  • Route Of Administration:
    • Intravitreal Injection: Prefilled Syringe (Multi Dose, Single Dose), Vial (Multi Dose, Single Dose)
    • Subconjunctival Injection
  • Distribution Channel:
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End User:
    • Ambulatory Surgical Centers
    • Hospitals
    • Ophthalmic Clinics
    • Specialty Clinics

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Product Type
8.1. Introduction
8.2. Aflibercept
8.3. Bevacizumab
8.4. Brolucizumab
8.5. Ranibizumab
9. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Therapeutic Area
9.1. Introduction
9.2. Age Related Macular Degeneration
9.3. Diabetic Macular Edema
9.4. Myopic Choroidal Neovascularization
9.5. Retinal Vein Occlusion
10. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Intravitreal Injection
10.2.1. Prefilled Syringe
10.2.1.1. Multi Dose Prefilled
10.2.1.2. Single Dose Prefilled
10.2.2. Vial
10.2.2.1. Multi Dose Vial
10.2.2.2. Single Dose Vial
10.3. Subconjunctival Injection
11. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Anti-vascular Endothelial Growth Factor Therapeutics Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Hospitals
12.4. Ophthalmic Clinics
12.5. Specialty Clinics
13. Americas Anti-vascular Endothelial Growth Factor Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Anti-vascular Endothelial Growth Factor Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Anti-vascular Endothelial Growth Factor Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. Regeneron Pharmaceuticals, Inc.
16.3.3. Bayer AG
16.3.4. Novartis AG
16.3.5. Eli Lilly and Company
16.3.6. Sanofi S.A.
16.3.7. Amgen Inc.
16.3.8. Pfizer Inc.
16.3.9. Viatris Inc.
16.3.10. Samsung Bioepis Co., Ltd
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 55. CANADA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 56. CANADA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 57. CANADA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. CANADA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 59. CANADA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 60. CANADA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 61. CANADA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 62. CANADA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. MEXICO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 64. MEXICO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 65. MEXICO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. MEXICO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 69. MEXICO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. MEXICO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. GERMANY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 105. GERMANY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 106. GERMANY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. GERMANY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 108. GERMANY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 109. GERMANY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 110. GERMANY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. GERMANY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. FRANCE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 113. FRANCE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 114. FRANCE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. FRANCE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 116. FRANCE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 117. FRANCE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 118. FRANCE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 119. FRANCE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. ITALY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 129. ITALY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 130. ITALY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. ITALY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 132. ITALY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 133. ITALY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 134. ITALY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. ITALY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. SPAIN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 137. SPAIN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 138. SPAIN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 139. SPAIN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 140. SPAIN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 141. SPAIN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 142. SPAIN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 143. SPAIN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. DENMARK ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 169. DENMARK ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 170. DENMARK ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. DENMARK ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 172. DENMARK ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 173. DENMARK ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 174. DENMARK ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. DENMARK ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. QATAR ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 185. QATAR ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 186. QATAR ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. QATAR ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 188. QATAR ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 189. QATAR ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 190. QATAR ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 191. QATAR ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. FINLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 193. FINLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 194. FINLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. FINLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 196. FINLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 197. FINLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 198. FINLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 199. FINLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. EGYPT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 217. EGYPT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 218. EGYPT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 219. EGYPT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 221. EGYPT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 222. EGYPT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. EGYPT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. TURKEY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 225. TURKEY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 226. TURKEY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. TURKEY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 228. TURKEY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 229. TURKEY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 230. TURKEY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. TURKEY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. NORWAY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 241. NORWAY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 242. NORWAY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. NORWAY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2030 (USD MILLION)
TABLE 244. NORWAY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2030 (USD MILLION)
TABLE 245. NORWAY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2030 (USD MILLION)
TABLE 246. NORWAY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. NORWAY ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. POLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 249. POLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 250. POLAND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. POLAND ANTI-VASCULAR ENDOT

Companies Mentioned

The companies profiled in this Anti-vascular Endothelial Growth Factor Therapeutics market report include:
  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals, Inc.
  • Bayer AG
  • Novartis AG
  • Eli Lilly and Company
  • Sanofi S.A.
  • Amgen Inc.
  • Pfizer Inc.
  • Viatris Inc.
  • Samsung Bioepis Co., Ltd

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 9.87 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.39 Billion
Compound Annual Growth Rate9.3%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Anti-vascular Endothelial Growth Factor Therapeutics Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Anti-vascular Endothelial Growth Factor Therapeutics Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Anti-Vascular Endothelial Growth Factor Therapeutics Market Report 2025 - Product Image

Anti-Vascular Endothelial Growth Factor Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Anti-vascular Endothelial Growth Factor Therapeutics (VEGF) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Anti-vascular Endothelial Growth Factor Therapeutics (VEGF) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 130 Pages
  • Global
From
Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2025 - Product Image

Vascular Endothelial Growth Factor Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • 90 Pages
  • Global
From
Vascular Endothelial Growth Factor Receptor 3 Antagonists - Pipeline Insight, 2025 - Product Image

Vascular Endothelial Growth Factor Receptor 3 Antagonists - Pipeline Insight, 2025

  • Drug Pipelines
  • 80 Pages
  • Global
From

About the Anti Vascular Endothelial Growth Factor Therapeutics Market

Anti-vascular endothelial growth factor (anti-VEGF) therapeutics have emerged within the field of cardiovascular drugs as targeted treatments primarily for conditions characterized by abnormal angiogenesis—the growth of new blood vessels. While anti-VEGF drugs were initially developed to counteract cancerous tumor growth, which often relies on angiogenesis for nutrient supply, their application in cardiovascular diseases also addresses conditions such as diabetic retinopathy and age-related macular degeneration, where excessive vascular proliferation can lead to vision loss. Cardiovascular diseases where VEGF plays a role include those where ischemia triggers pathological angiogenesis, although this remains a developing area of research and therapy. These medications function by inhibiting the VEGF pathway, thereby reducing the proliferation and permeability of endothelial cells that form the lining of blood vessels. Anti-VEGF therapeutics may be administered through various methods, including intravitreal injections, for conditions affecting the eye or systemically for broader impact. While these treatments offer novel mechanisms of action compared to traditional cardiovascular drugs such as statins and anticoagulants, they represent a specialized and evolving component of the therapeutic landscape, addressing a distinct subset of cardiovascular-related conditions. Companies active in the anti-VEGF therapeutics market include Regeneron Pharmaceuticals, which manufactures aflibercept, and Roche's Genentech, which produces ranibizumab and bevacizumab. Other players consist of Bayer AG and Novartis, all contributing to research, Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.